Background The number of elderly patients with psoriasis is steadily increasing in the Western world; nevertheless,
Introduction
Psoriasis is a chronic, inflammatory skin disease, its onset may occur at any age, 1 but with the increased life expectancy and quality of life, the number of psoriatic elderly patients is steadily increasing in the Western world. 2 The present scenario poses challenges for the therapeutic approach. Elderly patients suffer more from comorbidities such as hypertension, diabetes mellitus, chronic obstructive pulmonary and cardiovascular disease than younger patients, often resulting in polypharmacy and an increased risk of drug interactions.
reported that age over 65 years contributed to infection risk suggesting that advanced age is a risk factor for adverse events of biological drugs. 4 Thus, there is lack of information concerning safety and effectiveness of available treatments for psoriasis in the elderly, particularly about new biological agents. 5 Disease remission should be an objective for both younger patients and older patients, and biological therapy should be considered a treatment option for all patients.
Our aim was to describe our experience with all biological therapies currently used in the elderly (>65 years) psoriatic patients.
Materials and methods
This multicentric retrospective study recruited patients aged 65 years or more (the World Health Organization suggests to define an elderly person as having a chronological age of 65 years or above 6 ), who were diagnosed with plaque psoriasis or psoriatic arthritis and actually (December 2017) receiving biological drugs therapy (etanercept, adalimumab, infliximab, golimumab, certolizumab pegol, ustekinumab or secukinumab) at Psoriasis centre of Florence, Bologna, Pisa, Turin and Cagliari Dermatology Unit. Patients were included if we were able to track their health for a minimum of 1 year using patients' records. We collected information concerning patient characteristics (gender, date of birth, weight, height, date of diagnosis of psoriasis and comorbidities), previous and current systemic treatments and adverse events.
The efficacy of biologics was evaluated using the validated Psoriasis Area and Severity Index (PASI) at the following time points: week 0, week 16, week 28 and week 52. In addition, clinical efficacy was evaluated using PASI-75-90-100 (a 75, 90 and 100% reduction in the PASI score) at each time point. The safety profile was evaluated by monitoring adverse events (AEs), including their severity and by assessing clinical laboratory parameters, vital signs and physical examinations at each visit.
All data were entered into a Windows-based database (Microsoft Excel 2007); demographic data, patient characteristics efficacy and safety data were recorded and expressed as n (%) or means AE standard deviation (SD).
Results
Our study population included 266 psoriatic patients, 164 males (61.7%) and 102 females (38.3%), with mean age of 72.3 AE 5.7 years old (age range 65-85). The demographic and clinical characteristics of the study population are summarized in Table 1 .
Comorbidities including psoriatic arthritis, hypertension, dyslipidaemia, diabetes mellitus, cardiovascular, gastrointestinal and respiratory diseases, osteoporosis, thyroid dysfunction, depression and cancers are reported in detail in Table 1 .
The mean disease duration for the whole study population was 25.73 years AE 14.9 (adalimumab patients 23.97 AE 15.61, ustekinumab patients 21.03 AE 13.47, etanercept patients Adalimumab was the most commonly used biological (31.2% of patients), followed by ustekinumab (28.9%), etanercept (20.3%), secukinumab (15%), infliximab (3%), golimumab (1%) and certolizumab pegol (0.6%). For 128 of 266 patients, current biological therapy was the second biological therapy, and for 20, 6 and 1 patient, the third, fourth and fifth biological choice, respectively. Six patients combined methotrexate at the dose of 7.5-10 mg/weekly, 2 oral steroids and 1 cyclosporine (3 mg/kg). About preceding traditional systemic therapies, 240 of 266 were previously treated with methotrexate (7.5-15 mg/ weekly), or acitretin (10-30 mg/day), or cyclosporine (3.5-5 mg/Kg/day), or PUVA therapy or more than one of that.
Treatment efficacy was evaluated both as PASI-75, PASI-90 and PASI-100 achievement rate and as mean PASI score changes at weeks 16, 28 and 52. The dropout rate was 3%, 5% and 9% at 16, 28 and 52 weeks of therapy, respectively. Figure 1 shows the percentage of patients achieving PASI-75, PASI-90 and PASI-100 at each time. Figure 2a shows mean PASI score changes over 1-year treatment with current biological therapy. The PASI score at the baseline (week 0) ranged from 4 to 54; mean AE SD, 16.5 AE 7.1, which changed after biological administration to 3.7 AE 8 at week 16, 1.6 AE 2.1 at week 28 and 1.2 AE 2.1 at week 52 (Fig. 1) . We also performed a PASI score changes analysis for each drug (Fig. 2b) with detail of coefficient of variation per drug (Fig. 2c) .
The types and occurrence of adverse events were evaluated in all patients. Among 266 elderly psoriatic patients, 25 (9.4%) adverse events were reported during the observation period. The most frequent events were infections with 12 (48%) reports, followed by malignancies with four (16%) reports. About infections, we reported four cases of respiratory infections, three cases of urinary tract infections, two cases of mucocutaneous candidiasis, two cases of herpes zoster infection and one case of erysipelas. Regarding malignancies, we reported three cases of non-melanoma skin cancers and one case of vocal cord cancer. Other comorbidities were mild and are presented in Table 2 .
Discussion
Because of their high efficacy, biologics play a central role in the treatment of patients with moderate-to-severe psoriasis. However, their use has not been sufficiently investigated in elderly patients. Elderly patients are largely underrepresented in the clinical trials, for their comorbidities, higher risk of infections and cardiovascular disease resulting in limited data on the efficacy and safety. 3 Limited data are available in the literature regarding traditional and biological systemic treatments of psoriasis in the elderly population. 7, 8 A previous retrospective study evaluated the long-term efficacy and safety profile of etanercept and adalimumab, in the treatment of elderly patients affected by plaque-type psoriasis and psoriatic arthritis. and safety of ustekinumab in elderly patients with psoriasis, 10,11 and Chiricozzi et al. 12 reported a rapid PASI score reduction and maintenance in the long term in 27 elderly patients under treatment with infliximab. The German Psoriasis Registry PsoBest reported no differences in biologics prescription in patients aged 65 or over and patients aged 35-64. 13 Recently, Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis included also treatment recommendations for special psoriasis population, as elderly patients. The authors agreed that, for elderly patients requiring a systemic treatment, all therapy, including biologics, can be safely used, as long as they are appropriately screened and monitored.
14 To date, our study represents the broadest experience on the use of biological drugs in elderly psoriatic patients. We found that all biologics for psoriasis show a great efficacy also in elderly people.
The safety profile should be a primary need especially in elderly patients, in whom comorbidities should be taken into consideration when a long-term treatment is proposed, for the higher risk of side-effects and drug interactions. However, in our experience, none of the 266 patients developed any serious infection and the rate of malignancies was low (1.5%).
In conclusion, the age alone should not limit our therapeutic options. Further observational study using multiple data sources is needed to evaluate long-term effectiveness and safety for elderly psoriatic patients.
